Completed PHASE2 NCT00071812

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

Sponsor: Human Genome Sciences Inc.

Conditions Arthritis, Rheumatoid

Interventions Belimumab 1 mg/kg Belimumab 10 mg/kg Belimumab 4 mg/kg Placebo

Updated 7 times since 2017 Last updated: Aug 1, 2013 Started: Dec 31, 2003 Primary completion: Jan 31, 2005 Completion: Dec 31, 2005

A PHASE2 clinical study on Arthritis, Rheumatoid, this trial is completed. The trial is conducted by Human Genome Sciences Inc. and has accumulated 7 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Human Genome Sciences Inc.

Data source: Human Genome Sciences Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Ann Arbor, United States , Arlington, United States , Aventura, United States , Baltimore, United States , Baton Rouge, United States , Birmingham, United States , Boise, United States , Boston, United States , Brooklyn, United States and 46 more locations